Analysis of Predictive Markers of Response to Chemotherapy in Microdissected Components of Mixed Neuroendocrine/non-Neuroendocrine Carcinomas Abstract #733
Introduction: Mixed neuroendocrine (NE)/non-NE carcinomas lack pathological or molecular prognostic or predictive markers.
Aim(s): To analyze the pathological features and the expression of genes involved in DNA repair or synthesis in a cohort of mixed NE/non-NE carcinomas from different sites, as compared to patients’ outcome.
Materials and methods: A series of 42 cases (10 from lung, 18 from the gastro-entero-biliary system, 14 from the urogenital tract) was available for clinical and pathological correlates. In 35 cases, residual pathological material was adequate for microdissecting both NE and non-NE components and for quantitative PCR analysis of RRM1, ERCC1, TS and TOPOIIa. Control cases of pure NE and non-NE cancers were analyzed in parallel.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Marco Volante
Authors:
Volante M, Monica V, Birocco N, Daniele L, Busso S, La Rosa S, Brizzi M P, Berruti A, Scagliotti G, Papotti M
To read results and conclusion, please login ...
Further abstracts you may be interested in
#1204 Clinico-Pathologic and Survival Analysis of 211 GastroEnteroPancreatic G3 Neuroendocrine Carcinomas (GEP-NECs)
Introduction: GEP-NECs show Ki67>20% and/or >20 mitoses x10 HPF. Mixed AdenoNeuroendocrine Carcinomas (MANECs) are mixed exocrine-neuroendocrine neoplasms. NECs are associated with poor prognosis but recent findings have suggested that there is a fraction of patients showing a better than expected survival rate.
Conference: 12th Annual ENETS Conference (2015)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
#1510 Prognosis and Treatment Outcomes of Patients with Mixed Adenoneuroendocrine Carcinoma (MANEC)
Introduction: Mixed adenoneuroendocrine carcinomas (MANEC) are rare tumors, commonly treated in analogy to adenocarcinomas (AC) or neuroendocrine carcinomas (NEC) without systematic data regarding response to therapy.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Leonidas Apostolidis
Keywords:
MANEC, mixed adenoneuroendocrine carcinoma
#1691 Clinicopathological Features and Prognosis of 35 Patients with Gastric Neuroendocrine Carcinomas: A Single-Center Experience
Introduction: Gastric neuroendocrine carcinoma (G-NEC) is an uncommon and aggressive tumor of the stomach. The research on G-NEC is very limited.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: He Jiaqi
#1919 Prognosis and Treatment Outcomes of Patients with Mixed Adenoneuroendocrine Carcinoma (MANEC) – A Single Cancer Center Experience.
Introduction: Mixed adenoneuroendocrine carcinomas (MANEC) are rare tumors, commonly treated in analogy to adenocarcinomas (AC) or neuroendocrine carcinomas (NEC) without systematic data regarding the optimal treatment strategy.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Dr. med. Leonidas Apostolidis
Keywords:
MANEC, mixed adenoneuroendocrine carcinoma
#1159 Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract. ARGENTUM Group
Introduction: Mixed adenoneuroendocrine carcinomas of the gastrointestinal tract are rare neoplasms. In the 2000 WHO classification of endocrine tumors, such neoplasms were defined as mixed exocrine-endocrine tumors when each component represents at least 30% of the lesion. In the most recent WHO classification, such neoplasms are called “mixed adenoneuroendocrine carcinomas” (MANECs). They are a challenge for the diagnostic and treatment.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Ana Cabanne